Table 1.

Patient demographics

	DM (17 pts.)	Non-DM (44 pts.)	p
Age (years)	62.2 ± 7.1	62.0 ± 10.9	0.96
Men	12 (70.6%)	35 (79.5%)	0.51
Arterial hypertension	17 (100%)	39 (88.6%)	0.31
Current smoking	4 (23.5%)	15 (34.1%)	0.54
MI in past	7 (50%)	20 (54.1%)	0.8
Statin naive	3 (17.6%)	10 (22.7%)	0.98
Beta blockers	16 (94.1%)	28 (63.6%)	0.02
ACEI	15 (88.2%)	36 (81.8%)	0.71
Baseline Ch (mmol/l)	4.21 ± 0.75	4.31 ± 1.22	0.69
Follow-up Ch (mmol/l)	3.79 ± 0.99	3.35 ± 0.99	0.13
Change of Ch (mmol/l)	− 0.42 ± 0.89	− 0.97 ± 1.45	0.09
Baseline LDLc (mmol/l)	2.42 ± 0.53	2.46 ± 1.04	0.86
Follow-up LDLc (mmol/l)	2.12 ± 0.91	1.8 ± 0.66	0.21
Change of LDLc (mmol/l)	− 0.3 ± 0.52	− 0.66 ± 1.09	0.18
Baseline HDLc (mmol/l)	1.08 ± 0.38	1.23 ± 0.3	0.14
Follow-up HDLc (mmol/l)	1.09 ± 0.38	1.23 ± 0.27	0.19
Change of HDLc (mmol/l)	0.02 ± 0.52	− 0.01 ± 0.24	0.88
Baseline TAG (mmol/l)	1.59 ± 0.74	1.50 ± 0.88	0.4
Follow-up TAG (mmol/l)	1.52 ± 0.95	1.21 ± 0.52	0.22
Change TAG (mmol/l)	− 0.07 ± 0.96	− 0.29 ± 0.84	0.42
apo A (mmol/l)	0.08 ± 0.15	1.36 ± 0.32	0.16
apo B (mmol/l)	− 0.08 ± 0.22	− 0.13 ± 0.33	0.54
Baseline hs-CRP (mg/l)	2.28 ± 2.53	3.14 ± 4.31	0.49
Follow-up hs-CRP (mg/l)	4.87 ± 5.5	3.43 ± 4.0	0.3
Change of hs-CRP (mg/l)	2.6 ± 4.24	0.29 ± 5.1	0.13
Baseline glycemia (mmol/l)	7.04 ± 2.41	5.59 ± 0.78	0.0009
Follow-up glycemia (mmol/l)	7.51 ± 2.1	5.67 ± 0.78	< 0.0001
Change of glycemia (mmol/l)	0.04 ± 2.83	− 0.18 ± 1.45	0.69

MI myocardial infarction, ACEI angiotensin-converting enzyme inhibitors, Ch cholesterol, LDLc low density lipoprotein cholesterol, HDLc high density lipoprotein cholesterol, TAG triacyl glyceroles, apo A apolipoprotein A, apo B apolipoprotien B, hs-CRP high sensitive C reactive protein